Plain language review: the safety of relugolix combination therapy for advanced prostate cancer
Patients who receive relugolix combination therapy generally experience mild or moderate side effects, rather than serious side effects. No new safety issues were found during these studies. Patients maintained low testosterone levels. Patients and their doctors should discuss the benefits and possible harms of relugolix combination therapy to treat advanced prostate cancer.
Authors
- Sergio C. Gatoulis
- Paul Sieber (ORCID: https://orcid.org/0000-0002-6064-9683)
- Scott C. Flanders
- Michael S. Cookson (ORCID: https://orcid.org/0000-0001-8678-0551)
- Neal D. Shore (ORCID: https://orcid.org/0000-0001-5767-0548)
- Jared Thorley
- Jose De La Cerda (ORCID: https://orcid.org/0009-0008-6036-5753)
Institutions
- Intermountain Healthcare (US)
- Pfizer (United States) (US)
- Urology San Antonio (US)
- Urology Associates (US)
- Sumitomo Dainippon Pharma (United States) (US)
- Carolina Urologic Research Center (US)
- University of Oklahoma Health Sciences Center (US)
Publication Details
- Journal
- Future Oncology
- Published
- 2024-11-06
- DOI
- https://doi.org/10.1080/14796694.2024.2409543
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.42
Funders
- Pfizer